Arvinas, Inc. (ARVN) Balance Sheet

The balance sheet has contracted significantly over the past two years, with the asset base nearly halving. This trajectory is primarily fueled by a reduction in cash and a steep decline in deferred revenue, which fell from $599.2M to zero, indicating the company has recognized previously deferred milestone payments. The shrinking asset base, coupled with persistent negative retained earnings, signals that the business is not yet generating the internal capital to sustain or grow its asset base organically.

The current ratio is exceptionally high, indicating ample short-term liquidity. However, the cash balance itself has fluctuated dramatically quarter-to-quarter, a pattern inconsistent with a stable operating business. This volatility, when viewed alongside the prior finding of negative operating cash flow despite net income, implies that the company's liquidity buffer is not being replenished by core operations but by external, non-recurring events, making the cash position less predictable than the headline ratio suggests.

The equity section is dominated by a massive accumulated deficit, which is a hallmark of a pre-commercial biotech firm that has funded extensive R&D through equity issuances rather than profits. The stability of this deficit over recent quarters, despite periods of reported net income, suggests that any profits are being offset by ongoing losses or distributions, preventing meaningful equity accretion. This structure means the company's book value is almost entirely composed of contributed capital, not earned surplus.